MLH Cardiogenetics Consultation Service

By Ned Z. Carp, MD, President, MLH Medical Staff, and Lawrence L. Livornese, Jr., MD, Chairman, Department of Medicine, MLH

As you may be aware November 14 is Genetic Counseling Awareness Day.  With continuing advances in genetic testing, as well as wider availability and more affordability, genetic evaluation is becoming an important part of personalized care.  Simultaneously, the genetic testing landscape is becoming increasingly complex to navigate.  

For nearly two decades, we have had a strong cancer genetics program at Main Line Health.  In an effort to meet our patients’ and providers’ growing needs around genetics, the program has expanded. We are extremely pleased to introduce the MLH Cardiogenetics Program, and the MLH Prenatal Genetics Program.

A sampling of candidate patients that may be considered for referral to cardiogenetics include those with certain conduction abnormalities, both dilated and hypertrophic cardiomyopathies, diseases of the aorta, and significant dyslipidemias.  Indications for prenatal genetics include abnormal prenatal test results, exposures during pregnancy, carrier testing, advanced maternal or paternal age, personal or family history of genetic disease, among others. 

All patients seen within the MLH genetics programs are directed back to their managing physicians for continued care, and a report including findings, test results and guidelines for follow up is provided to both patient and provider.  

Please see attached fliers on the MLH Cardiogenetics and Prenatal Programs.

MLH Cardiogenetics Program Info Sheet

MLH_Genetic_InfoSheet_Prenatal

For more information, contact:

Cristina Nixon, MS, Cardiology Genetic Counselor                            nixonc@mlhs.org

Taylor Reeve, MS, Prenatal Graduate Genetic Counselor                 reevet@mlhs.org  

Rachael Brandt, PhD, MS, Program Manager                                   brandtr@mlhs.org

 

Posted in Uncategorized | Leave a comment

Clinical Trials of the Week: Main Line Health is recruiting patients for six lung cancer clinical studies

By Donna Loyle, communications specialist, LIMR

November is Lung Cancer Awareness Month, which makes this an ideal time to highlight the Main Line Health lung cancer clinical trials that currently are recruiting patients. Trials are available for patients diagnosed with small cell (SCLC) and non-small cell lung cancer (NSCLC).

  • E4512 is testing the oral drug crizotinib in patients with NSCLC and are positive for ALK gene.
  • C30610/RTOG 0538 is a radiotherapy study for patients with SCLC confined to one hemithorax.
  • The Alchemist trial (A151216) seeks to advance genetic research related to NSCLC.
  • A081105 is testing the oral drug erlotinib in patients with NSCLC and are positive for EGFR gene.
  • NRG LU002 is studying chemotherapy with or without radiotherapy in patients with NSCLC.
  • Lung-MAP is a master screening protocol for patients with recurrent NSCLC. If assigned to a sub-study, participants undergo a new, targeted cancer therapy or a combination of standard care.

The principal investigators for these trials are Albert DeNittis, MD, and Paul Gilman, MD. For more, email cancertrials@mlhs.org or visit www.mainlinehealth.org/lungclinicaltrials.

Posted in Uncategorized | Leave a comment

Announcement: Bindu Kumar, MD, System Medical Director of Employee Health and Safety

By Rick Mankin, MD, President, Main Line HealthCare

I am pleased to announce that Bindu Kumar, MD, has been promoted to the role of System Medical Director of Employee Health and Safety. During her time as the Associate Medical Director of Occupational and Travel Health, Dr. Kumar has provided expertise and support in developing and bringing System integration to Main Line Health’s occupational health and safety programs.  

As part of this expanded role, Dr. Kumar will be able to devote her time and expertise to additional System-wide initiatives related to employee health and safety, related regulatory issues, and the employee accountable care organization (eACO). Dr. Kumar will continue to report to me, while working with both Dr. Norton and myself. She will also continue to provide clinical services within the Occupational Health Services department.  I am very pleased that Dr. Kumar has agreed to take on this new role.

 

Posted in Uncategorized | Leave a comment

Announcement of Funding Opportunities from Sharpe – Strumia Research Foundation

Application deadline for 2020 is January 16

  • Grants are available to support original research by health care professionals at Bryn Mawr Hospital and other Main Line Health hospitals.
  • Priority will be given to research proposals by practicing physicians and other healthcare professionals at Bryn Mawr Hospital.  Projects that have the potential to lead to advances in clinical practice are encouraged.
  • Funds for travel to national meetings for presentation of results are available with prior approval from the Treasurer. Reimbursement for publication costs of funded studies in peer reviewed journals is available.
  • A maximum of $50,000 per project is available for a period of 1 year starting on July 1, 2020.  A few grants will be considered for an award of $75,000 IF THERE IS CLEAR JUSTIFICATION in the research and budget sections explaining why the additional funds are crucial to the project.  Most awards will be for $50,000 in an effort to encourage as many research projects as possible.  If the project is not completed within one year, the investigator may apply for funding in the next funding cycle.
  • Assistance in refining your research proposal prior to submission is available from experienced investigators.  Such assistance is strongly encouraged especially for investigators who do not have extensive research experience.
  • Investigators agree to abide by the Foundation’s  intellectual property policy which is available on the Foundation’s website (http://www.mainlinehealth.org/sharpe-strumia)

Please visit  http://www.mainlinehealth.org/sharpe-strumia  and/or contact Louise Gethers for information on application forms and procedures.

Submit a completed PDF version of your proposal to: SharpeStrumiaFoundationOffice@MLHS.ORG and nine (9) hardcopies

by noon on January 16, 2020 to:

Louise Gethers

Sharpe – Strumia Research Foundation Office

130 S. Bryn Mawr Avenue

1st Floor / H-Wing, Room 110

Bryn Mawr, PA  19010

For further information contact Louise Gethers at (484) 337-4244 or email GethersL@mlhs.org

Visit us on the web at http://www.mainlinehealth.org/sharpe-strumia

Posted in Uncategorized | Leave a comment

Cannabidiol as potential therapeutic agent to be discussed at two seminars

By Donna Loyle, communications specialist, LIMR

All clinicians and researchers are welcome to two upcoming seminars hosted by the Lankenau Institute for Medical Research (LIMR) that will explore the potential future use of cannabidiol (CBD) as a therapeutic agent.

CBD is a chemical in the Cannabis sativa plant, also known as marijuana or hemp. More than 80 chemicals, known as cannabinoids, have been identified in the plant. The 2018 U.S. Farm Bill made it legal to sell hemp and hemp products in the United States, which is why CBD is getting more scrutiny in recent months.

LIMR seminar

William A. Kinney, PhD, chief scientific officer for biopharmaceutical company Kannalife Inc., will give the LIMR seminar “New Cannabidiol-Like Molecules as Pharmaceutical and Cosmetic Ingredients.”

Dr. Kinney’s long career in the pharmaceutical industry included stints at Wyeth and Magainin Pharmaceuticals. At Johnson & Johnson, he pursued drug targets for cardiovascular indications. He invented KLS-13019 for Kannalife Sciences, a company focused on cannabinoid therapeutics. Most recently, Dr. Kinney co-founded Enterin Inc., where he is leading the manufacturing of squalamine phosphate for Parkinson’s disease.

His seminar will be held on Thursday, November 14, from 2 to 3 p.m. in McLean Conference Room in the Annenberg Center at Lankenau Medical Center.

Dynamic Duo talk

The second seminar, a Dynamic Duo session, is entitled “Can Cannabidiol Reduce Peripheral Neuropathy, a Common Difficult Side Effect of Chemotherapy?” Speakers Marisa Weiss, MD, and Melvin Reichman, PhD, will define the hallmarks of the cannabinoid drug class and the endocannabinoid system and discuss potential medical applications and known adverse events.

Dr. Weiss, director of breast radiation oncology at Lankenau Medical Center, is a leading figure in the breast cancer community, having started the education and advocacy website breastcancer.org. She also serves as an adjunct investigator at LIMR. Her present research interests focus on the use of cannabinoid compounds to relieve side effects of breast cancer treatment.

Dr. Reichman is a senior investigator at LIMR and founder and director of the LIMR Chemical Genomics Center where he designed and built a patented automated repository and screening technology to help accelerate drug discovery. Before joining LIMR, he served as a director of drug discovery at major biotechnology firms.

Their Dynamic Duo talk will take place on Tuesday, November 19. Lunch at 11:45 a.m. Talk begins at noon. In Annenberg Center 101 at Lankenau Medical Center.

 

Posted in Uncategorized | Leave a comment

Vaping/Electronic Cigarettes & Lung Illness

By Joseph Bushra, MD, President LMC Medical Staff

Please click on the attached presentation to learn about the current medical knowledge we have on vaping/electronic cigarettes and lung illness. Leah Lande, MD gave this informative presentation at the October LMC Medical Staff Meeting.

If there is anyone on the Medical Staff that would like to present this important topic to students, possibly at their child’s school or at a nearby middle and/or high school; Dr. Lande is making a separate slide set available for you to use.  An interested physician should contact Dr. Lande (Landel@mlhs.org) with your request and indicate the date and location of the presentation being given.

Vaping for Med Staff Meeting Oct 15 2019

Posted in Clinician News | Leave a comment

2019-2020 MLH Medical Staff Meetings

Attendance at 50% (1) Hospital Staff meeting per Calendar Year is required for Active Staff members by the MLH Medical Staff Bylaws.

You may attend any ONE of the following meetings, at the hospital of your choice, whether that hospital is/is not your primary facility.

THERE ARE NO EXCUSED ABSENCES.

Spring 2020 Meetings

Tuesday, April 21, 2020 6:00PM Paoli Hospital – Potter Room
Tuesday, May 5, 2020 6:00PM Riddle Hospital – Springfield Country Club
Thursday, May 14, 2020 5:30PM Bryn Mawr Hospital – Pennypacker Auditorium
Tuesday, June 2, 2020 5:00PM Lankenau Medical Center – Center Pew

Auditorium

Questions? Contact the Medical Staff Affairs Office at 484-337-8031

Posted in Uncategorized | Leave a comment

Clinical Trial of the Week: New treatment trial for patients with advanced kidney cancer

By Donna Loyle, communications specialist, LIMR 

PDIGREE is new phase III clinical trial for patients with untreated metastatic kidney cancer. Researchers seek to determine if the addition of cabozantinib to the usual treatment — which is ipilimumab and nivolumab followed by nivolumab alone — is better at treating cancer than the usual treatment without it.

Inclusion criteria:

  • Must have histologically documented renal cell carcinoma with clear cell component, including patients who have sarcomatoid features
  • Must have metastatic disease, including visceral, lymph node, other soft tissue and bone, measurable per RECIST 1.1
  • No prior treatment with PD-1, PD-L1, or CTLA-4 targeting agents, or any other drug or antibody specifically targeting T-cell co-stimulation or checkpoint pathways
  • Must have no active autoimmune disease requiring ongoing therapy

Other inclusion criteria apply.

 All patients in this study receive nivolumab IV and ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles.

  • Patients with PD receive cabozantinib PO daily on days 1-28.
  • Those with CR receive nivolumab IV on day 1; treatment repeats every 28 days.
  • Patients with non-CR/non-PD receive nivolumab IV on day 1, and one group (the experimental arm) also receives cabozantinib PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

This study is approved for all Main Line Health acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email cancertrials@mlhs.org or visit www.mainlinehealth.org/research/clinical-trials/pdigree

Posted in Uncategorized | Leave a comment

Monday is the last day to get your mandatory flu vaccination

The Main Line Health 2019-2020 mandatory flu vaccination program is underway for employees, physicians, specified healthcare professionals and volunteers. Since 2010, MLH policy has required all physicians, specified health professionals, employees, contracted clinical personnel and volunteers to be vaccinated against influenza as a condition of employment or use of MLH facilities.

Vaccinations are free and will take place across MLH until December 2, 2019, which is the deadline for compliance with our flu vaccination policy. Open the PDF to view the complete vaccination schedule.

An MLH badge is required at the time of vaccination.

2019-2020 Flu Schedule

Posted in Clinician News | Leave a comment

It’s Pager Time – 6 Daylights Savings Reminders

The start and end of Daylight Savings Time is a great time to give your paging device a bi-annual checkup. As a health system, pagers act as fundamental tool for disseminating short pieces of information to a large number of people in a matter of seconds. Use these 6 important reminders to ensure the proper functionality and message receipt of your essential device.

  1. Change Your Batteries: You’ve likely heard this one before, but it’s worth repeating. If that interminable beeping sound seems to be getting fainter with each day, check your pagers battery display screen. Once your battery life is less than ½ it’s time for a replacement.
  2. Delete Old Messages: One of the most common complaint’s we hear is “I’m not getting any pages.” Please remember that unlike cellphone text messages, pagers have a much smaller message storage capacity. Once the pager’s memory is full, users may experience issues with missed or delayed pages.
  3. Change the Pager Time: One of the most important things to remember about your paging device is that it does not feature a “real time clock” that automatically adjusts the time when we fall back or spring forward. Users must manually set the time on their pagers to ensure that the message notification time is reflected accurately.
  4. Take Stock of Group Pager Lists: Daylight Savings Time isn’t just a great time to perform routine maintenance on your individual devices. It’s also a perfect time for staff, who own, manage or maintain group pagers lists to review department lists, emergency code lists and special event lists. Upon review, be sure to contact the Service Desk to add/delete group members or provide an update if the pager group is no longer needed.
  5. Clean Out Drawers:Check the desk drawers, cabinets and lockers inside your unit for paging devices that may no longer be in use by your department. Broken, damaged and mislabeled devices may need to be replaced or returned to the vendor. Equipment that is no longer in use may be accruing costly and unnecessary charges.
  6. Clean the Screen: Do not clean your pager device with disinfectants or chemical based cleaners. These products tend to easily infiltrate your device display screen and can cause discoloration and message distortion. Instead, wipe your device with a dry or slightly damp cloth.
Posted in Uncategorized | Leave a comment